Needle-free vaccine delivery☆

Giudice, Erin; Campbell, James D.

doi:10.1016/j.addr.2005.12.003

Cited by 433 publications

(246 citation statements)

References 83 publications

Supporting

Mentioning

244

Contrasting

Unclassified

Order By: Relevance

“…Most traditional vaccines are not cost-effective because they cannot be stored at room temperature (RT), instead requiring that the ''cold chain'' be preserved en route from vaccine manufacturer to the field of vaccination (i.e., that no gap be allowed in the refrigeration) (10). The cost of preserving that cold chain for currently used vaccines is estimated at between $200 and $300 million a year (10). Further, if inappropriately processed or disposed of, the needles and syringes used for the vaccination can pose the threats of environmental contamination and secondhand spread of infectious disease.…”

mentioning

confidence: 99%

“…In fact, the Bill and Melinda Gates Foundation and the National Institutes of Health have proposed that mucosal vaccines be a focus of future vaccine development (9), a vision underlying the foundation of the Gates' research initiative, ''Grand Challenges in Global Health'' (9). Most traditional vaccines are not cost-effective because they cannot be stored at room temperature (RT), instead requiring that the ''cold chain'' be preserved en route from vaccine manufacturer to the field of vaccination (i.e., that no gap be allowed in the refrigeration) (10). The cost of preserving that cold chain for currently used vaccines is estimated at between $200 and $300 million a year (10).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Rice-based mucosal vaccine as a global strategy for cold-chain- and needle-free vaccination

Nochi

Takagi

Yuki

et al. 2007

Proc. Natl. Acad. Sci. U.S.A.

308

285

View full text Add to dashboard Cite

Capable of inducing antigen-specific immune responses in both systemic and mucosal compartments without the use of syringe and needle, mucosal vaccination is considered ideal for the global control of infectious diseases. In this study, we developed a rice-based oral vaccine expressing cholera toxin B subunit (CTB) under the control of the endosperm-specific expression promoter 2.3-kb glutelin GluB-1 with codon usage optimization for expression in rice seed. An average of 30 g of CTB per seed was stored in the protein bodies, which are storage organelles in rice. When mucosally fed, rice seeds expressing CTB were taken up by the M cells covering the Peyer's patches and induced CTB-specific serum IgG and mucosal IgA antibodies with neutralizing activity. When expressed in rice, CTB was protected from pepsin digestion in vitro. Rice-expressed CTB also remained stable and thus maintained immunogenicity at room temperature for >1.5 years, meaning that antigen-specific mucosal immune responses were induced at much lower doses than were necessary with purified recombinant CTB. Because they require neither refrigeration (cold-chain management) nor a needle, these rice-based mucosal vaccines offer a highly practical and cost-effective strategy for orally vaccinating large populations against mucosal infections, including those that may result from an act of bioterrorism. mucosal immunity ͉ protein body ͉ oral vaccine ͉ IgA ͉ cholera toxin B subunit

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

Rice-based mucosal vaccine as a global strategy for cold-chain- and needle-free vaccination

Nochi

Takagi

Yuki

et al. 2007

Proc. Natl. Acad. Sci. U.S.A.

308

285

View full text Add to dashboard Cite

show abstract

“…Aerosol immunization is a prime example of such an alternative. It offers many advantages including ease and speed of application by nonmedical personnel, noninvasiveness resulting in greater social acceptance, reduced risk of cross-contamination of blood-born infectious agents, diminished medical waste, and potentially lower costs (3,4). NYVAC and MVA are two highly attenuated recombinant poxvirus-based smallpox vaccines.…”

mentioning

confidence: 99%

Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic

Corbett

Bogers

Heeney

et al. 2008

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Each year, approximately five million people die worldwide from putatively vaccine-preventable mucosally transmitted diseases. With respect to mass vaccination campaigns, one strategy to cope with this formidable challenge is aerosol vaccine delivery, which offers potential safety, logistical, and cost-saving advantages over traditional vaccination routes. Additionally, aerosol vaccination may elicit pivotal mucosal immune responses that could contain or eliminate mucosally transmitted pathogens in a preventative or therapeutic vaccine context. In this current preclinical non-human primate investigation, we demonstrate the feasibility of aerosol vaccination with the recombinant poxvirus-based vaccine vectors NYVAC and MVA. Real-time in vivo scintigraphy experiments with radiolabeled, aerosol-administered NYVAC-C (Clade C, HIV-1 vaccine) and MVA-HPV vaccines revealed consistent mucosal delivery to the respiratory tract. Furthermore, aerosol delivery of the vaccines was safe, inducing no vaccine-associated pathology, in particular in the brain and lungs, and was immunogenic. Administration of a DNA-C/NYVAC-C prime/boost regime resulted in both systemic and anal-genital HIV-specific immune responses that were still detectable 5 months after immunization. Thus, aerosol vaccination with NYVAC and MVA vectored vaccines constitutes a tool for large-scale vaccine efforts against mucosally transmitted pathogens.MVA HPV ͉ non-human primate ͉ NYVAC HIV ͉ preclinical study ͉ aerosol vaccine assessment

show abstract

“…However, for practical and cultural reasons researchers have tended to focus only on oral, nasal, and pulmonary administration. 1 Needlefree vaccines offer many advantages over traditional vaccination approaches including convenience, cost, ease of administration and disposal.…”

mentioning

confidence: 99%

Current prospects and future challenges for nasal vaccine delivery

Yusuf

Kett

2016

Human Vaccines & Immunotherapeutics

124

View full text Add to dashboard Cite

Nasal delivery offers many benefits over traditional approaches to vaccine administration. These include ease of administration without needles that reduces issues associated with needlestick injuries and disposal. Additionally, this route offers easy access to a key part of the immune system that can stimulate other mucosal sites throughout the body. Increased acceptance of nasal vaccine products in both adults and children has led to a burgeoning pipeline of nasal delivery technology. Key challenges and opportunities for the future will include translating in vivo data to clinical outcomes. Particular focus should be brought to designing delivery strategies that take into account the broad range of diseases, populations and healthcare delivery settings that stand to benefit from this unique mucosal route. In this review the current state of the art in nasal vaccine delivery will be described along with future prospects. A brief introduction to the anatomy and physiology of the nasal cavity will highlight the advantages and disadvantages of the route. Encapsulation and presentation methods along with particular formulation considerations for the nasal route will also be discussed.There are many mucosal routes which have been regarded as potential sites for vaccine delivery such as oral, nasal, pulmonary, conjunctival, rectal and vaginal mucosa. However, for practical and cultural reasons researchers have tended to focus only on oral, nasal, and pulmonary administration. 1 Needlefree vaccines offer many advantages over traditional vaccination approaches including convenience, cost, ease of administration and disposal.There are several needle free methods of vaccination such as transdermal delivery and mucosal delivery. 2,3 Mucosal immunization has been successfully used in human vaccination. The human mucosal immune system is large and specialized in performing inspection for foreign antigens to protect the surfaces themselves and of course human body interior. Since most infections affect or start from mucosal surfaces, using a mucosal route of vaccination is of great interest and provides a rational reason to induce a protective immune response. 3 Nasal delivery of vaccine offers an easily accessible route to the immune system.The nose has the function of olfactory detection (sense of smell) and also filtration, humidification and temperature control of air as it enters the respiratory system. Moving from front to back the areas of the nasal cavity are the nasal vestibule, the respiratory region, and the olfactory region. The nasal cavity is divided by the septum to form the left and right nares, which lead into the left and right choana before opening onto the nasopharynx at the top of the throat. The turbinates bound the nasal walls and are responsible for air conditioning and the large mucosal surface area of the nasal cavity. The nose is also the main port of entry for many pathogens. The first barrier to foreign bodies is hair at the entrance to the nares, the nostrils, which successfully keeps ou...

show abstract

Needle-free vaccine delivery☆

Cited by 433 publications

References 83 publications

Rice-based mucosal vaccine as a global strategy for cold-chain- and needle-free vaccination

Rice-based mucosal vaccine as a global strategy for cold-chain- and needle-free vaccination

Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic

Current prospects and future challenges for nasal vaccine delivery

Contact Info

Product

Resources

About